Innovative Genomics Institute supports Kampmann Lab in search for new therapies for neurodegeneration
Kampmann Lab, July 2018
A major goal of the Kampmann Lab is the identification of new therapeutic targets for neurodegenerative diseases, such as Alzheimer’s disease. The lab has developed a CRISPR-based screening platform to identify genes and pathways controlling disease processes in neurons and glia from human patient-derived induced pluripotent stem cells. The Innovative Genomics Institute, directed by CRISPR pioneer Dr. Jennifer Doudna, named Dr. Martin Kampmann an IGI Investigator, and supports the Kampmann lab to facilitate the translation of research insights to therapeutic strategies. Kampmann lab members Dr. Avi Samelson, postdoctoral fellow, Ruilin Tian, graduate student, and Gita Rohanitazangi, staff research associate, are leading the research supported by the IGI.